IRIS
STAGNO, Fabio
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 1.088
NA - Nord America 473
SA - Sud America 392
EU - Europa 300
AF - Africa 33
OC - Oceania 2
Totale 2.288
Salva come PNG Salva come JPEG
Nazione #
SG - Singapore 537
US - Stati Uniti d'America 419
BR - Brasile 338
HK - Hong Kong 216
CN - Cina 142
VN - Vietnam 111
IT - Italia 71
DE - Germania 61
FR - Francia 32
GB - Regno Unito 26
MX - Messico 26
AR - Argentina 21
AT - Austria 21
RU - Federazione Russa 21
CA - Canada 20
IN - India 18
NL - Olanda 13
ZA - Sudafrica 13
BD - Bangladesh 9
EC - Ecuador 9
ID - Indonesia 8
PL - Polonia 8
SE - Svezia 8
TR - Turchia 8
UA - Ucraina 8
FI - Finlandia 7
MA - Marocco 7
VE - Venezuela 7
JP - Giappone 6
TN - Tunisia 6
AZ - Azerbaigian 5
ES - Italia 5
PE - Perù 5
UY - Uruguay 5
CL - Cile 4
IQ - Iraq 4
PK - Pakistan 4
UZ - Uzbekistan 4
IE - Irlanda 3
IL - Israele 3
LT - Lituania 3
PA - Panama 3
PT - Portogallo 3
CI - Costa d'Avorio 2
DO - Repubblica Dominicana 2
JO - Giordania 2
LK - Sri Lanka 2
PY - Paraguay 2
SN - Senegal 2
TT - Trinidad e Tobago 2
AE - Emirati Arabi Uniti 1
AM - Armenia 1
AO - Angola 1
AU - Australia 1
BE - Belgio 1
BG - Bulgaria 1
BN - Brunei Darussalam 1
CO - Colombia 1
CZ - Repubblica Ceca 1
DK - Danimarca 1
DZ - Algeria 1
EE - Estonia 1
EG - Egitto 1
GE - Georgia 1
JM - Giamaica 1
KG - Kirghizistan 1
KZ - Kazakistan 1
LU - Lussemburgo 1
LV - Lettonia 1
MD - Moldavia 1
MK - Macedonia 1
MN - Mongolia 1
NP - Nepal 1
NR - Nauru 1
SK - Slovacchia (Repubblica Slovacca) 1
TW - Taiwan 1
Totale 2.288
Salva come PNG Salva come JPEG
Città #
Singapore 223
Hong Kong 215
Ashburn 79
Beijing 77
Los Angeles 47
Ho Chi Minh City 46
São Paulo 31
Dallas 27
Messina 26
Hanoi 25
Munich 25
New York 20
Nuremberg 17
Vienna 15
Mexico City 14
Redondo Beach 14
Rio de Janeiro 14
Brooklyn 12
Buffalo 12
Frankfurt am Main 12
Montreal 12
Amsterdam 11
Porto Alegre 11
Johannesburg 10
Atlanta 9
Belo Horizonte 9
Boston 9
Rome 9
Poplar 8
Stockholm 8
Catania 7
Düsseldorf 7
Santo André 7
Warsaw 7
Brasília 6
Chicago 6
Da Nang 6
Lauterbourg 6
Santa Clara 6
Seattle 6
Tokyo 6
Curitiba 5
Franca 5
Haiphong 5
Mumbai 5
New Delhi 5
San Francisco 5
São José dos Campos 5
Baku 4
Bauru 4
Bexley 4
Jakarta 4
Limina 4
Moscow 4
Nova Iguaçu 4
Palermo 4
Phoenix 4
Tashkent 4
Trapani 4
Tunis 4
Barretos 3
Campinas 3
Dhaka 3
Dublin 3
Garanhuns 3
Guarulhos 3
Guayaquil 3
Houston 3
Hải Dương 3
Iguaí 3
Joinville 3
Lima 3
London 3
Manchester 3
Milan 3
Montevideo 3
Orem 3
Panama City 3
Piracicaba 3
Portsmouth 3
Salvador 3
Secaucus 3
Thái Nguyên 3
Tianjin 3
Toronto 3
Turku 3
Valparaíso de Goiás 3
Abidjan 2
Adrano 2
Amman 2
Ankara 2
Antakya 2
Araras 2
Asunción 2
Baie-D'Urfé 2
Barra do Choça 2
Betim 2
Bắc Ninh 2
Cajamar 2
Campina Grande 2
Totale 1.307
Salva come PNG Salva come JPEG
Nome #
Highlights on the Effects of Non-Coding RNAs in the Osteonecrosis of the Jaw 63
B-ALL relapses after autologous stem cell transplantation associated with a shift from e1a2 to e14a2 BCR-ABL transcripts: A case report 59
Prospective assessment of NGS-detectable mutations in CML patients with nonoptimal response: The NEXT-in-CML study 55
Determinants of frontline tyrosine kinase inhibitor choice for patients with chronic-phase chronic myeloid leukemia: A study from the Registro Italiano LMC and Campus CML 52
Chronic myeloid leukemia management at the time of the COVID-19 pandemic in Italy. A campus CML survey 52
Oxidative Stress and Chronic Myeloid Leukemia: A Balance between ROS-Mediated Pro- and Anti-Apoptotic Effects of Tyrosine Kinase Inhibitors 48
Influence of Vitamin D and Its Analogues in Type-B Lymphomas 45
BCR-ABL1 doubling-times and halving-times may predict CML response to tyrosine kinase inhibitors 45
BCR-ABL nuclear entrapment kills human CML cells: Ex vivo study on 35 patients with the combination of imatinib mesylate and leptomycin B 43
Targeting chronic myeloid leukemia stem/progenitor cells using venetoclax-loaded immunoliposome 42
The Italian Multicentric Randomized OPTkIMA Trial on Fixed vs Progressive Intermittent TKI Therapy in CML Elderly Patients: 3-Years of Molecular Response and Quality of Life Monitoring After Completing the Treatment Plan 41
A Treatment-free Interval Allowed by Ponatinib as Fourth-line Therapy 40
Hematological Malignancies in Older Patients: Focus on the Potential Role of a Geriatric Assessment Management 40
Age and dPCR can predict relapse in CML patients who discontinued imatinib: The ISAV study 40
A novel system for semiautomatic sample processing in chronic myeloid leukaemia: Increasing throughput without impacting on molecular monitoring at time of sars-cov-2 pandemic 39
Age influences initial dose and compliance to imatinib in chronic myeloid leukemia elderly patients but concomitant comorbidities appear to influence overall and event-free survival 38
Health-related quality of life of newly diagnosed chronic myeloid leukemia patients treated with first-line dasatinib versus imatinib therapy 37
Chk1 inhibition restores inotuzumab ozogamicin citotoxicity in CD22-positive cells expressing mutant p53 37
No Benefit from Hydroxyurea Pre-Treatment in Frontline Chronic Myeloid Leukemia Therapy and Evidence of Quantitative Changes in the BCR::ABL1 Transcript Level 36
Retinal Vessel Analysis and Microvascular Abnormalities in Patients with Philadelphia-Negative Chronic Myeloproliferative Neoplasms 35
Cardiovascular toxicity in patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors in the real-life practice: Identification of risk factors and the role of prophylaxis 35
Imatinib increases cytotoxicity of melphalan and their combination allows an efficient killing of chronic myeloid leukemia cells 34
A case of high-risk AML in a patient with advanced systemic mastocytosis 34
Increased tumor burden in patients with chronic myeloid leukemia after 36 months of imatinib discontinuation 33
Adherence and future discontinuation of tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia. A patient-based survey on 1133 patients 32
Italian Physicians’ Perceptions about the Role of Asciminib in Later Lines Chronic Myeloid Leukemia in Clinical Practice: A GIMEMA Survey 32
All-trans-retinoic-acid- and growth-factor-mediated induction of alkaline phosphatase activity in freshly isolated chronic myeloid leukemia cells 32
Current Strategies and Future Directions to Achieve Deep Molecular Response and Treatment-Free Remission in Chronic Myeloid Leukemia 30
Utilization of Machine Learning in the Prediction, Diagnosis, Prognosis, and Management of Chronic Myeloid Leukemia 29
Clinical Relevance of ABCB1, ABCG2, and ABCC2 Gene Polymorphisms in Chronic Myeloid Leukemia Patients Treated With Nilotinib 28
Chronic fatigue is the most important factor limiting health-related quality of life of chronic myeloid leukemia patients treated with imatinib 28
Using Artificial Intelligence to Enhance Myelodysplastic Syndrome Diagnosis, Prognosis, and Treatment 27
All-trans retinoic acid might also induce apoptosis in freshly isolated chronic myeloid leukemia cells 27
The Q-LAMP method represents a valid and rapid alternative for the detection of the BCR-ABL1 rearrangement in Philadelphia-positive Leukemias 26
Imatinib dose escalation in 74 failure or suboptimal response chronic myeloid leukaemia patients at 3-year follow-up 26
Cutaneous vasculitis in non Hodgkin's lymphoma 24
CD34 expression in adult acute lymphoblastic leukemia 24
Acute myeloid leukemia occurring in a patient with polycythemia vera in treatment with hydroxyurea [5] 24
Charlson comorbidity index and adult comorbidity evaluation-27 scores might predict treatment compliance and development of pleural effusions in elderly patients with chronic myeloid leukemia treated with second-line dasatinib 23
Utility of flow cytometry as a screening tool for transplant donors for chronic lymphocytic leukemia 23
Unsuccessful dasatinib therapy in a refractory patient with chronic lymphocytic leukemia 23
Arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life practice are predicted by the Systematic Coronary Risk Evaluation (SCORE) chart 23
Biochemical fingerprinting of dried blood serum from chronic lymphocytic leukemia patients by Raman spectroscopy: Towards prognostic classification 22
Colony-forming cell assay detecting the co-expression of JAK2 V617F and BCR-ABL1 in the same clone: A case report 22
BRIT1/MCPH1 expression in chronic myeloid leukemia and its regulation of the G2/M checkpoint 22
Managing chronic myeloid leukemia for treatment-free remission: A proposal from the GIMEMA CML WP 21
Combined inhibition of bcl2 and bcr-abl1 exercises anti-leukemia activity but does not eradicate the primitive leukemic cells 21
COVID-19 infection in chronic myeloid leukaemia after one year of the pandemic in Italy. A Campus CML report 20
Nilotinib 300 mg twice daily: An academic single-arm study of newly diagnosed chronic phase chronic myeloid leukemia patients 19
Modeling the Bone Marrow Niche in Multiple Myeloma: From 2D Cultures to 3D Systems 17
Non ABL-directed inhibitors as alternative treatment strategies for chronic myeloid leukemia 17
Uncommon long-term survival in a patient with chronic myeloid leukemia 17
Persistence of Drug-Resistant Leukemic Stem Cells and Impaired NK Cell Immunity in CML Patients Depend on MIR300 Antiproliferative and PP2A-Activating Functions 16
Treatment-free remission in chronic myeloid leukemia patients treated front-line with nilotinib: 10-year followup of the GIMEMA CML 0307 study 16
Next-generation sequencing improves BCR-ABL1 mutation detection in Philadelphia chromosome-positive acute lymphoblastic leukaemia 16
Efficacy of dasatinib in a very elderly CML patient expressing a rare E13A3 BCR-ABL1 fusion transcript: A case report 16
Dasatinib first-line: Multicentric Italian experience outside clinical trials 16
Septic Shock in Hematological Malignancies: Role of Artificial Intelligence in Predicting Outcomes 15
Hyperdiploidy associated with a high BCR-ABL transcript level may identify patients at risk of progression in chronic myeloid leukemia 15
Aberrant phenotypic expression of the T-cell-associated antigen CD8 on B-cell chronic lymphocytic leukemia cells 15
Gut Microbiota Dysbiosis and Dietary Interventions in Non-Hodgkin B-Cell Lymphomas: Implications for Treatment Response 15
SETBP1 induces transcription of a network of development genes by acting as an epigenetic hub 15
Impact of Different Cell Counting Methods in Molecular Monitoring of Chronic Myeloid Leukemia Patients 14
Myeloma Patient With Brugada Syndrome and Successful Lenalidomide Treatment 14
T cell receptor δ-chain gene rearrangement in a novel case of adult NK cell leukemia 14
Biochemical fingerprinting of dried blood serum from chronic lymphocytic leukemia patients by Raman spectroscopy: Towards prognostic classification 14
Bispecific Antibodies and Antibody–Drug Conjugates in Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma, Focusing on Diffuse Large B-Cell Lymphoma 14
Recurrent arterial occlusive events in patients with chronic myeloid leukemia treated with second- and third-generation tyrosine kinase inhibitors and role of secondary prevention 13
Myeloid Derived Suppressor Cells (MDSCs) are increased and exert immunosuppressive activity together with Polymorphonuclear Leukocytes (PMNs) in chronic myeloid leukemia patients 13
Efficacy of nilotinib in a CML patient expressing the three-way complex variant translocation t(2;9;22) 13
Navigating the Landscape of Exosomal microRNAs: Charting Their Pivotal Role as Biomarkers in Hematological Malignancies 13
High BCR::ABL1 Expression Defines CD34+ Cells with Significant Alterations in Signal Transduction, Short-Proliferative Potential and Self-Renewal Ability 13
Observational study of chronic myeloid leukemia italian patients who discontinued tyrosine kinase inhibitors in clinical practice 12
Rapid decline of philadelphia-positive metaphases after nilotinib treatment in a CML patient expressing a rare e14a3 BCR-ABL1 fusion transcript: A case report 12
Pro-Inflammatory and Pro-Oxidative Changes During Nilotinib Treatment in CML Patients: Results of a Prospective Multicenter Front-Line TKIs Study (KIARO Study) 12
Outcome of 82 chronic myeloid leukemia patients treated with nilotinib or dasatinib after failure of two prior tyrosine kinase inhibitors 12
DNA Methylation in Ph-Negative Myeloproliferative Neoplasms: Prognostic Role and Therapeutic Implications 12
Integrated genomic, functional, and prognostic characterization of atypical chronic myeloid leukemia 12
Reduced Absolute Count of Monocytes in Patients Carrying Hematological Neoplasms and SARS-CoV2 Infection 12
Digital PCR improves the quantitation of DMR and the selection of CML candidates to TKIs discontinuation 12
Long term follow-up of frontline Dasatinib in older patients with chronic myeloid leukemia in chronic phase treated outside clinical trials: a real-life cohort observational study 12
On the road to treatment-free remission in chronic myeloid leukemia: what about ‘the others’? 11
Clinical relevance of the association of interferon alfa to imatinib in chronic myeloid leukemia therapy 11
Incidence, risk factors and management of pleural effusions during dasatinib treatment in unselected elderly patients with chronic myelogenous leukaemia 11
Risk of progression in chronic phase-chronic myeloid leukemia patients eligible for tyrosine kinase inhibitor discontinuation: Final analysis of the TFR-PRO study 11
Infliximab therapy in hematologic malignancies: Handle with care (Comment) 10
Second-line dasatinib therapy improved compliance and deep molecular responses in imatinib-intolerant chronic myeloid leukemia patients 10
Low-density lipoprotein (LDL) levels and risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib 10
The new Systematic Coronary Risk Evaluation (SCORE2 and SCORE2‑OP) estimates the risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib or ponatinib 10
Incidence of second primary malignancies and related mortality in patients with imatinib-treated chronic myeloid leukemia 10
Real‐World Efficacy Profile of Compassionate Use of Asciminib in an Italian, Multi‐Resistant Chronic Phase Chronic Myeloid Leukemia (CML‐CP) Patient Population 10
Guidelines for the management of pleural effusions during dasatinib treatment in chronic myeloid leukemia 10
Deep Molecular Response Rate in Chronic Phase Chronic Myeloid Leukemia: Eligibility to Discontinuation Related to Time to Response and Different Frontline TKI in the Experience of the Gimema Labnet CML National Network 9
Curcumin and Acute Myeloid Leukemia: Synergistic Effects with Targeted Therapy 9
Frontline Dasatinib Treatment in a “Real-Life” Cohort of Patients Older than 65 Years with Chronic Myeloid Leukemia 9
Decoding Immunodeficiencies with Artificial Intelligence: A New Era of Precision Medicine 9
Prognostic Factors for Overall Survival In Chronic Myeloid Leukemia Patients: A Multicentric Cohort Study by the Italian CML GIMEMA Network 9
Influence of complex variant chromosomal translocations in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors 9
First-hit SETBP1 mutations cause a myeloproliferative disorder with bone marrow fibrosis 9
Treatment patterns in patients with chronic-phase chronic myeloid leukaemia in routine clinical practice: The simplicity Italian population 9
Totale 2.286
Salva come PNG Salva come JPEG
Categoria #
all - tutte 9.476
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 9.476
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2023/202429 0 0 0 0 0 0 0 0 0 11 2 16
2024/20251.149 20 0 0 24 54 17 149 137 264 81 126 277
2025/20261.327 146 223 229 331 365 33 0 0 0 0 0 0
Totale 2.505